Prot# C-1802: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety & Efficacy of Natalizumab, When Added to Avonex® (Interferon beta-1a), in Subjects w/ Relapsing-Remitting Multiple Sclerosis